Know Labs Announces The KnowU, Its Wearable Non-Invasive Continuous Glucose Monitor
Portfolio Pulse from Benzinga Newsdesk
Know Labs, Inc. (NYSE:KNW) announced the KnowU, a wearable non-invasive continuous glucose monitor (CGM), incorporating a proprietary sensor intended for FDA submission. The KnowU, smaller and lighter than its prototype, features on-board computing, built-in machine learning, and aims to enhance diabetes management by being durable, eliminating disposables, and offering easy connectivity with a mobile app. Know Labs plans to use the KnowU for accelerated data collection in FDA clinical trials, targeting a diverse range of glycemic levels and populations. The company, holding over 270 patents, aims to make diabetes care more accessible and affordable.

February 27, 2024 | 2:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Know Labs, Inc. announces the KnowU, a wearable glucose monitor with proprietary technology, aiming for FDA approval. The device is designed to be user-friendly and support extensive data collection for clinical trials.
The announcement of the KnowU, a non-invasive CGM device, is significant for Know Labs as it marks a major step towards commercializing their technology. The device's innovative features and the company's focus on FDA approval could positively impact investor sentiment and the company's stock price in the short term. The emphasis on accessibility and affordability in diabetes care, along with the proprietary technology and extensive patent portfolio, further strengthens the company's position in the market.
CONFIDENCE 90
IMPORTANCE 95
RELEVANCE 100